Appendix 4C – Quarterly
October 31, 2019
Imagion Biosystems has released its Quarterly Cashflow Report for the period ending 30 September 2019. Read Appendix 4C.
Category: Investor updates
Renounceable Rights Issue — Notification to Ineligible Shareholders
October 29, 2019
Imagion Biosystems has announced a notification to ineligible shareholders regarding the renounceable pro-rata offer of 28 October 2019. Read the notification.
Renounceable Rights Issue Letter to Shareholders
October 29, 2019
Imagion Biosystems has announced a letter to shareholders regarding the 28 October 2019 announcement of a renounceable pro-rata offer. Read the letter to shareholders.
Pro-Rata Renounceable Rights Issue — Indicative Close Date
October 29, 2019
Imagion Biosystems announces an amendment to the previously announced close date. For the purposes of the Pro-Rata Renewable Rights Issue, the indicative close date is
Pro-Rata Renounceable Rights Issue — Amended Timetable
October 29, 2019
Imagion Biosystems has announced and amendment to the proposed timetable for the Pro-Rata Renounceable Rights Issue as announced on Monday, 28 October 2019. Read the
Appendix 3B
October 28, 2019
Imagion Biosystems has announced “Appendix 3B, New issue announcement, application for quotation of additional securities and agreement.” Read Appendix 3B.
Renounceable Pro-Rata Offer Prospectus
October 28, 2019
Imagion Biosystems announces a pro-rata offer prospectus. Read the pro-rata offer prospectus.
Pro-Rata Renounceable Rights Issue
October 28, 2019
Imagion Biosystems is pleased to announce a pro-rata renounceable rights issue (Offer) to fund the manufacture of the nanoparticle material, the undertaking of a first-in-human
Investor Presentation — MagSense® Imaging
October 28, 2019
Imagion Biosystems announces the presentation “MagSense® Imaging: Early Detection of Cancer Through Targeted Imaging.” See the presentation “MagSense® Imaging“.
Nanoparticle Manufacturing Update
October 25, 2019
Imagion Biosystems is pleased to provide an update on its progress and plans for manufacturing of its proprietary nanoparticle formulation in advance of the first